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Abstract
Background: Asthma is a biologically heterogeneous disease and development of novel therapeutics requires
understanding of pathophysiologic phenotypes. There is uncertainty regarding the stability of clinical characteristics
and biomarkers in asthma over time. This report presents the longitudinal stability over 12 months of clinical
characteristics and clinically accessible biomarkers from ADEPT.
Methods: Mild, moderate, and severe asthma subjects were assessed at 5 visits over 12 months. Assessments
included patient questionnaires, spirometry, bronchodilator reversibility, fractional exhaled nitric oxide (FENO), and
biomarkers measured in induced sputum.
Results: Mild (n = 52), moderate (n = 55), and severe (n = 51) asthma cohorts were enrolled from North America and
Western Europe. For all clinical characteristics and biomarkers, group mean data showed no significant change from
visit to visit. However, individual data showed considerable variability. FEV1/FVC ratio showed excellent
reproducibility while pre-bronchodilator FEV1 and FVC were only moderately reproducible. Of note bronchodilator
FEV1 reversibility showed low reproducibility, with the nonreversible phenotype much more reproducible than the
reversible phenotype. The 7-item asthma control questionnaire (ACQ7) demonstrated moderate reproducibility for
the combined asthma cohorts, but the uncontrolled asthma phenotype (ACQ7 > 1.5) was inconstant in mild and
moderate asthma but stable in severe asthma. FENO demonstrated good reproducibility, with the FENO-low
phenotype (FENO < 35 ppb) more stable than the FENO-high phenotype (FENO ≥ 35 ppb). Induced sputum
inflammatory phenotypes showed marked variability across the 3 sputum samples taken over 6 months.
Conclusions: The ADEPT cohort showed group stability, individual stability in some parameters e.g. low FEV1/FVC
ratio, and low FENO, but marked individual variability in other clinical characteristics and biomarkers e.g. type-2
biomarkers over 12 months. This variability is possibly related to seasonal variations in climate and allergen
exposure, medication changes and acute exacerbations. The implications for patient selection strategies based on
clinical biomarkers may be considerable.
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Background
Asthma is a heterogeneous disease where clinical and/or
biomarker phenotyping increases the probability of suc-
cess with novel therapies. Thus anti-IL13 monoclonal
antibodies (mAb) are more efficacious in T helper 2
(Type-2) driven inflammation characterized by bio-
markers e.g. periostin [1], fractional exhaled nitric oxide
(FENO) [1], and dipeptidyl peptidase 4 [2]. The anti-
interleukin 5 therapies are effective in those with ele-
vated markers of eosinophilic inflammation in blood and
sputum [3–6]. Similarly, an anti-IgE mAb, omalizumab,
is more effective in patients with high periostin level,
high FENO and high blood eosinophil count [7].
However, whether or not these phenotypic characteris-
tics of asthma are stable in a single patient over time re-
mains to be determined. Such a question is crucial since
entry into a clinical trial, or selecting a therapy in the
clinic, may be based on a single phenotypic assessment.
Spontaneous variability, seasonal variation, allergen ex-
posure, acute infections, medication changes, and pa-
tient adherence could all drive instability in phenotype.
The ADEPT (Airways Disease Endotyping for Person-
alized Therapeutics) study profiled clinical characteris-
tics and biomarkers in mild, moderate and severe
asthma compared to healthy non-atopic controls, with a
view to identifying clinical and biological phenotypes.
The study design and population characteristics have
been previously reported in detail [8].
Accordingly, an important objective of ADEPT was to
follow mild, moderate and severe asthma subjects over
1 year to determine the stability of identified clinical and
biological phenotypes, a period which would cover sea-
sonal changes (allergen, climate, infection) and also
allow spontaneous variability. Herein, we report the clin-
ical and biomarker characteristics and how these varied
over the 12-month course of the study.
Methods
The study received institutional ethics approval at all sites.
All subjects provided written informed consent to partici-
pate. The clinicaltrials.gov identifier is NCT01274507. A
complete description of the study design, recruited popu-
lation and disease characteristics has been previously re-
ported in detail [8].
Population
Approximately 150 asthma subjects (50 subjects in each
of 3 asthma categories (mild, moderate, severe) were
planned for inclusion in the study. The National Heart,
Lung, and Blood Institute (NHLBI) expert panel report
[9] was adapted for classification of severity based on
lung function and controller medication levels. All sub-
jects were non-smokers for ≥ 1 year at the initial screen-
ing visit and had ≤ 10 pack-year history of smoking.
Severity of asthma was defined at screening based on
the level of background medications and lung function
as previously reported [8]. Briefly, 52 mild (no asthma
controller medications, forced expired volume in 1 s
(FEV1) > 80 % predicted), 52 moderate (low-moderate
dose inhaled corticosteroid (ICS), FEV1 between 60 to
<80 % predicted), and 55 severe (high-dose ICS, FEV1
between 50 to <80 % predicted) asthma subjects were
enrolled. The definition of low, medium and high ICS
levels was based on the National Institutes of Health
Clinical Practice Guidelines: Expert Panel Report 3:
Guidelines for the Diagnosis and Management of
Asthma., 2007 [9].
Study design and visits
Detailed study design and methodologies have previously
been reported in detail but a brief summary is provided
below [8].
Asthma subjects underwent screening, then if enrolled
attended the baseline visit. Further clinical assessment/
biomarker visits occurred at 3, 6 and 12 months, with
induced sputum sampling repeated at the 6 month visit.
These 3, 6 and 12 month visits were intended to evaluate
variability over time including the impact of seasons.
During the study, investigators or treating physicians
were permitted to make adjustments to asthma medica-
tions as medically needed.
Clinical and biomarker assessments
Assessments measured longitudinally included pre-
bronchodilator (pre-BD) and post-bronchodilator (post-
BD) spirometric variables (FEV1, FVC, PEFR, and re-
versibility), the 7-item asthma control questionnaire
ACQ7 [10], asthma quality of life questionnaire (AQLQ)
[11], FENO, and induced sputum inflammatory cells.
Detailed methods have been previously reported [8].
Induced sputum
The method for induction and processing of sputum
using the plug selection method has been described pre-
viously [12, 13]. Briefly, all study participants underwent
induction for 21 min divided into three 7-min sessions
of using an aerosol of hypertonic saline (in increasing
concentrations of 3, 4, and 5 %). For those with FEV1 ≥
50– < 60 % predicted, induction was performed with
normal/isotonic saline (0.9 %). Subjects with post-BD
FEV1 < 50 % predicted were not induced.
The plug selection method was used for this study
with plugs treated with dithiothreitol. The detailed
methodology has been previously reported [8].
Statistical considerations
Significance of differences between groups was evaluated
using General Linear Model analyses, using log-
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transformed data when necessary to satisfy assumption of
normality of distributions (for FENO and sputum eosino-
phils, specifically). Correlations between variables were
evaluated by calculation of the Pearson correlation coeffi-
cient (r).
Within-subject correlations over longitudinal visits for
the clinical and clinical biomarker assessments were
summarized via the intraclass correlation coefficient
(ICC) (CRAN-R-project software (https://CRAN.R-pro-
ject.org, version 3.2) package ‘ICC’ version 2.2.1). Confi-
dence intervals (95 %) were estimated using the exact
confidence limit equations appropriate for unbalanced
data (THD option: [14]). The number of measurements
per subject used in the ICC estimation is reported based
on the equations from Lessells and Boag [15]. Box-and-
whisker plot representations of distributions in figures
show the median and interquartile range (box), mini-
mum and maximum range (whiskers), mean (‘+’ symbol),
and diamond symbols the values for each individual sub-
ject/sample.
Results
The study enrolled 52 mild, 55 moderate, and 51 severe
asthma subjects in North America and Europe from
2010–2013.
Disposition of subjects in study
The retention of subjects was high in ADEPT as shown
in Table 1. Seventeen of 158 asthma subjects withdrew
prematurely (1 for a non-serious adverse event (AE); 5
withdrew consent, 2 for pregnancy, 4 for sponsor deci-
sions, 2 were lost to follow-up and 3 withdrew for other
reasons) as previously detailed [8].
Stability of background medications
Changes in background medications may reflect changes
in asthma control but can also impact longitudinal sta-
bility, however few subjects had changes as detailed
below.
Table 1 Retention of ADEPT asthma subjects in study
Number of subjects % of number of subjects at baseline
Baseline Month 3 Month 6 Month 12 Baseline Month 3 Month 6 Month 12
Mild 52 48 47 45 100 % 92 % 90 % 87 %
Moderate 55 50 50 49 100 % 91 % 91 % 89 %
Severe 51 48 47 47 100 % 94 % 92 % 92 %
Total 158 146 144 141 100 % 92 % 91 % 89 %
Table 2 Asthma disease characteristics by cohort at baseline visit
Asthma severity cohort
Cohorts* Mild Moderate Severe P-value ***
N (total/sputum) 52/32 55/38 51/40
Age (years) 33.7 (13.1) 45.0 (11.6) 46.2 (12.1) <10−6
Pre-BD FEV1 (% predicted) 92.7 (14.3) 73.6 (10.4) 65.4 (12.7) < 10−6
Pre-BD FEV1/FVC ratio 0.77 (0.08) 0.66 (0.09) 0.61 (0.09) < 10−6
Post-BD FVC (% predicted) 105.0 (15.5) 96.4 (11.4) 94.0 (15.1) 0.0004
BDR (% change in FEV1) 8.5 (8.3) 15.2 (10.3) 18.3 (14.5) 0.0016
BDR (mL change in FEV1) 265.1 (231.7) 335.2 (234.3) 355.7 (270.6) 0.45
ACQ7 0.84 (0.69) 1.33 (0.71) 1.92 (1.01) < 10−6
AQLQ 5.86 (0.93) 5.68 (1.11) 5.09 (1.28) 0.0016
FENO (ppb) ** 32.9 (+64.2/−16.9) 29.1 (+61.0/−13.9) 28.8 (+64.7/−12.9) 0.59
Sputum eosinophils, % of WBC ** 1.12 (+5.38/−0.93) 3.12 (+13.62/−2.54) 2.70 (+12.27/−2.21) 0.033
Sputum lymphocytes, % of WBC 1.29 (1.42) 0.98 (1.19) 0.94 (1.25) 0.48
Sputum macrophages, % of WBC 50.20 (31.17) 32.10 (21.45) 43.04 (26.46) 0.019
Sputum neutrophils, % of WBC 43.88 (30.90) 56.99 (26.13) 48.10 (25.52) 0.13
* Mean (standard deviation) reported by cohort, unless otherwise indicated
** Geometric mean (asymmetric standard deviation) reported by cohort
*** p-value (ANOVA F-test for differences across asthma severity cohorts (based on log-transformed data when geometric means reported)
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Oral corticosteroids (OCS)
Two severe asthma subjects were on OCS during
screening and at the baseline visit; one discontinued
OCS at day 27 post-baseline whereas the second
continued OCS throughout the study. Only a minor-
ity of subjects received OCS bursts during the study
(4/51 mild (7.8 %), 3/55 moderate (5.5 %) and 8/51
severe (15.7 %) asthma subjects), which was greater
for mild, but reduced for moderate and severe
asthma subjects compared to the year prior to entry
into the study (4 % of mild, 15 % of moderate, and
27 % of severe asthma).
Inhaled corticosteroids
Two mild asthma subjects were on ICS at baseline: 1
started ICS after screening while another reported taking
ICS during screening. Three mild subjects started ICS
post-baseline and 3 moderate subjects increased ICS
dose post-baseline visit.
Within-subject, longitudinal variation of asthma
characteristics
Baseline characteristics have been previously reported
[8], with the baseline values for the longitudinally
assessed variables presented in Table 2.
For the longitudinally assessed clinical characteristics,
mean values did not significantly vary over the course of
the study (data not shown). However, there was obvious
intra-individual variability across the visits, with the
within-subject changes from the baseline visit for the
longitudinally assessed characteristics presented in
Figs. 1, 2 and 3. This intra-individual variability was sta-
tistically summarized by the ICC method (see Table 3).
There was no consistent difference in variability by
severity.
Longitudinal stability of lung function
Pre-BD FEV1/FVC ratio and PEFR showed the highest
ICC values (>0.79) across all severities reflecting low
Fig. 1 Longitudinal stability of lung function parameters. Changes from baseline visit (y-axis) for the indicated clinical variable (at top of row of
plots) are shown by visit (x-axis), stratified by asthma severity cohort (indicated at top of plot)
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variability. Percent predicted Pre-BD FEV1 and FVC had
lower ICC values (0.60–0.75) for moderate and severe
asthma cohorts.
Longitudinal stability of bronchodilator response
Bronchodilator reversibility (BDR) was assessed at
screening and at every study visit. BDR expressed as
% change or absolute change had low ICC values for
cross-visit correlations ranging between 0.39–0.45
across severities, reflecting low stability of this meas-
ure (see Table 3).
Defining a reversible phenotype as a change from
baseline of ≥12 % and ≥200mls, the reversible pheno-
type was highly variable across cohorts, with screen-
ing vs. baseline concordances of 44, 36, and 56 % for
mild, moderate, and severe cohorts, respectively and
variable concordance rates at the 3, 6, and 12 month
visits (Fig. 4a). In contrast, the non-reversible pheno-
type was more stable than the reversible phenotype,
with screening vs. baseline concordances of 72, 61,
and 69 % for mild, moderate, severe cohorts, respect-
ively and similar concordance rates seen at the 3, 6,
and 12 month visits (Fig. 4b).
Longitudinal stability of ACQ7
ACQ was less stable (ICC 0.55–0.61) than AQLQ, spiro-
metric measures, or FENO across asthma severities
(Table 3). In mild asthma (non-ICS-treated), for those
with an ACQ > 1.5 at baseline (uncontrolled asthma),
there was considerable variability with only 40 % con-
cordance at month 3 (Fig. 5a), in contrast to those with
an ACQ < 1.5 at baseline (controlled asthma), with 87 %
concordance at month 3, (Fig. 5b). For moderate asthma,
there was considerable variability for the ACQ ≥ 1.5
phenotype at baseline (Fig. 5a), with only 55 % concord-
ance at month 3, but 80 % concordance for those with a
baseline ACQ < 1.5 at month 3 (Fig. 5b). In severe
asthma, there was 79 % concordance at month 3 for
ACQ ≥ 1.5 at baseline (Fig. 5a) but only 65 % concord-
ance at month 3 with the baseline ACQ < 1.5 (Fig. 5b).
Thus moderate asthmatic subjects showed a greater ten-
dency to become controlled over time (ACQ < 1.5) com-
pared to mild asthma while most severe asthmatics who
were uncontrolled at baseline, remained uncontrolled
later on. Similar observations pertain to months 6 and
12.
AQLQ showed greater stability over time compared to
ACQ with ICC values in the 0.74 to 0.82 range, with
mild asthma (who were non-ICS-treated) showing
greater variability than moderate and severe asthma
(Table 3).
Longitudinal stability of FENO
FENO was measured at screening, and at all study visits.
Longitudinal stability was moderate in mild asthma with
mean (95 % CL) ICC values 0.64 (0.51–0.75), but higher
in moderate 0.78 (0.69–0.86), and severe asthma 0.75
(0.65–0.84) (Table 3).
Using 35 ppb as a cutoff to define high- and low-
FENO [16] at baseline, the high-FENO phenotype
showed reduced concordances for the severe asthma co-
hort at the month 3, 6 and 12 visits compared to the
Fig. 2 Longitudinal stability of lung function parameters. Changes from baseline visit (y-axis) for the indicated clinical variable (at top of row of
plots) are shown by visit (x-axis), stratified by asthma severity cohort (indicated at top of plot)
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moderate cohort. Of note, there were 58 and 54 % con-
cordances for mild asthma at month 12 and severe
asthma at month 6, respectively. The moderate cohort
maintained high concordances for the FENO-high
phenotype, with the lowest concordance at month 6
(82 %). Overall, there were 85, 75, and 72 %
concordances at months 3, 6, and 12, respectively, across
the 3 severity cohorts combined for the FENO-high de-
fined at baseline (Fig. 6a).
In contrast, the FENO-low phenotype at baseline was
generally stable across severity cohorts at subsequent
study visits. Mild asthma had the lowest concordance
Fig. 3 Longitudinal stability of patient reported outcomes and FENO. Changes from baseline visit (y-axis) for the indicated clinical variable (at top
of row of plots) are shown by visit (x-axis), stratified by asthma severity cohort (indicated at top of plot)
Table 3 Intraclass correlation coefficients for clinical characteristics over all study visits
ICC (95 % CI) [number of visits] Mild (n = 52) Moderate (n = 55) Severe (n = 51) All asthma (n = 158)
FEF2575, pre-BD 0.80 (0.73–0.87) [4.5] 0.76 (0.68–0.84) [4.6] 0.67 (0.56–0.77) [4.7] 0.82 (0.78–0.86) [4.6]
FEV1/FVC, pre-BD 0.86 (0.80–0.91) [4.5] 0.79 (0.71–0.86) [4.6] 0.84 (0.77–0.89) [4.7] 0.88 (0.85–0.90) [4.6]
FEV1 % predicted, pre-BD 0.72 (0.62–0.81) [4.5] 0.60 (0.48–0.71) [4.6] 0.64 (0.52–0.75) [4.7] 0.81 (0.77–0.85) [4.6]
FVC % predicted, pre-BD 0.79 (0.71–0.86) [4.5] 0.62 (0.51–0.73) [4.5] 0.75 (0.66–0.83) [4.7] 0.79 (0.74–0.83) [4.6]
PEFR, pre-BD 0.83 (0.76–0.89) [4.5] 0.81 (0.73–0.87) [4.6] 0.86 (0.80–0.91) [4.7] 0.86 (0.83–0.89) [4.6]
FEV1 change post-BD (% predicted) 0.45 (0.32–0.59) [4.5] 0.39 (0.26–0.53) [4.5] 0.39 (0.26–0.54) [4.6] 0.42 (0.35–0.50) [4.5]
FEV1 change post-BD (L) 0.45 (0.32–0.59) [4.5] 0.53 (0.41–0.66) [4.5] 0.47 (0.34–0.61) [4.6] 0.48 (0.41–0.56) [4.5]
FENO, ppb (log) 0.64 (0.51–0.75) [3.6] 0.78 (0.69–0.86) [3.6] 0.75 (0.65–0.84) [3.6] 0.73 (0.67–0.78) [3.6]
ACQ-7 0.61 (0.48–0.73) [3.6] 0.57 (0.43–0.69) [3.6] 0.55 (0.41–0.69) [3.7] 0.65 (0.58–0.71) [3.6]
AQLQ 0.74 (0.63–0.82) [3.6] 0.82 (0.74–0.88) [3.6] 0.78 (0.68–0.85) [3.7] 0.79 (0.74–0.83) [3.6]
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(77 %) at Month 3 for the FENO-low phenotype defined
at baseline. In contrast, there were 84, 89, and 88 % con-
cordances for the FENO-low phenotype at months 3, 6,
and 12, respectively, across the 3 severity cohorts
(Fig. 6b).
Longitudinal stability of induced sputum inflammatory
cells
Sputum was induced at screening (required for eligibil-
ity), baseline, and at the 6 month visit. There were 92,
73, and 55 asthma subjects with acceptable differential
counts available at the screening, baseline, and Month 6
visits, respectively, with 117 subjects having acceptable
counts for at least one visit. Of the 92 asthma subjects
with acceptable screening visit counts, only 52 and 41
had acceptable counts at the baseline and month 6 visits,
respectively.
Seventy two asthma subjects had acceptable counts for
at least 2 visits and 42 subjects for all 3 visits. For all
asthma severities combined, the proportion of spMAC
Fig. 4 Longitudinal stability of the bronchodilator reversible phenotype. The number of subjects (y-axis, number label) with reversible (red bars) and
non-reversible (blue bars) phenotypes for response to bronchodilator, based on cut-off of change in FEV1 of 12 % and 200 ml, at the indicated visit
(x-axis) are shown for subjects that were reversible (a) or non-reversible (b) at the screening visit, stratified by asthma severity cohort
a
b
Fig. 5 Longitudinal stability of asthma control phenotype. The number of subjects (y-axis, number label) with poorly controlled (ACQ ≥1.5, red)
and controlled (ACQ < 1.5, blue) asthma phenotypes, at the indicated visit (x-axis) are shown for subjects with ACQ≥ 1.5 (a) or ACQ < 1.5 (b) at
the baseline visit, stratified by asthma severity cohort
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demonstrated the highest ICC across the screening,
baseline, and month 6 measurements (0.71) followed by
spNEU (0.63), and spEOS (0.58) (Fig. 7). The very low
stability of spLYM was perhaps related to the very low
proportions of this cell. When taking asthma severity
into account, there was low stability of eosinophil pro-
portions in mild asthma probably related to the low pro-
portion of mild subjects with sputum eosinophilia.
Considering commonly-used definitions for 4 sputum
phenotypes, paucigranulocytic (spNEU < 60 % and
spEOS < 3 %), neutrophilic (spNEU ≥ 60 %), eosinophilic
(spEOS ≥ 3 %) [17] and mixed inflammatory phenotypes
(spNEU ≥ 60 % and spEOS ≥ 3 %), differing stability pat-
terns were observed (Table 4). Comparing the baseline
visit to screening (n = 52), concordance was highest for
the neutrophilic phenotype (62 %), followed by the
mixed (57 %), eosinophilic and paucigranulocytic pheno-
types (both 50 %) (Table 4). Comparing the 6-month
visit to screening (n = 41), concordance was highest for
the paucigranulocytic (77 %) and eosinophilic (71 %)
phenotypes, followed by the neutrophilic (43 %) and
mixed phenotypes (29 %) (Table 5).
Longitudinal stability was also assessed sub-setting on
only spNEU (NEU-high = spNEU ≥ 60 % vs. NEU-low =
spNEU <60 %) or only spEOS (EOS-high = spEOS ≥ 3 %
vs. EOS-low = spEOS < 3 %) phenotypes. Comparing
baseline to screening, concordance was highest for the
EOS-low (84 %) and NEU-high (75 %) phenotypes, and
moderate for the NEU-low (68 %) and EOS-high (61 %)
phenotypes (Table 4). Comparing 6-month to screening
measurements (n = 41), concordance was highest for the
EOS-high (85 %) and NEU-low (85 %) phenotypes, and
moderate for the NEU-high (71 %) and EOS-high (67 %)
phenotypes (Table 5).
Appreciating the uncertainty in the appropriate cut-off
value for sputum neutrophils relating to pathology in
a
b
Fig. 6 Longitudinal stability of FENO phenotypes. The number of asthma subjects (y-axis, number label) with FENO-high (≥35 ppb, red bars) and
FENO-low (<35 ppb, blue bars) phenotypes, at the indicated visit (x-axis) are shown for subjects with FENO≥ 35pbb (a) or FENO < 35 ppb (b) at
the baseline visit, stratified by asthma severity cohort
Fig. 7 Longitudinal stability of sputum leukocyte subsets. Intraclass correlation coefficients (ICC) and 95 % confidence intervals are shown for the
indicated sputum leukocyte subset (% of total sputum leukocytes; x-axis), stratified by asthma severity cohort
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asthma, additional cut-off values were tested. Screening-
to-baseline visit concordance for neutrophil high/low
phenotypes using 40, 60, and 80 % cut-offs were 75, 71,
and 80 %, respectively. The concordances for screening-
to-month 6 visit were 87, 84, and 81 %, respectively.
Also, the ICC for proportion of neutrophils over the 3
visits, which does not require a cut-off to be specified,
demonstrated moderate stability (ICC = 0.63, 95 % CI:
0.52–0.72).
Discussion
The ADEPT study profiled mild, moderate, and severe
asthma subjects and accrued biomarker data across mul-
tiple matrices in the majority of subjects and evaluated
several of these matrices repeatedly over 12 months. Of
note, while most clinical and biomarker characteristics
were stable in the severity cohorts as a whole, there was
marked individual variability in most parameters.
For lung function, pre-BD FEV1/FVC ratio and PEFR
showed the best reproducibility, while pre-BD FEV1 and
FVC % predicted were more variable possibly reflecting
fluctuations in asthma control, in keeping with the
inherent variability of airway smooth muscle contraction
in asthma.
One of the most interesting findings of the present
study is the poor reproducibility of the BDR over a 12-
months period. The factors underlying this variability
likely include spontaneous change in asthma control,
and patient adherence as well as technical factors includ-
ing the withholding of bronchodilators before testing as
dictated by the protocol, the time of the BDR (due to
circadian variability) and inherent variability in the spir-
ometry test itself.
Moreover, there was low concordance from visit to
visit in terms of defining a reversible phenotype. The
vast majority of clinical trials in asthma require demon-
stration of BDR for eligibility predominantly due to
regulatory requirements to objectively “confirm” the
diagnosis of asthma, although COPD can demonstrate
significant reversibility as well [18]. This requirement
undoubtedly excludes a substantial number of subjects
with asthma from studies. Moreover, it appears that re-
versibility is not a stable phenotype and perhaps eligibil-
ity criteria for studies could be relaxed in this regard, if
Table 4 Concordance for 4 sputum inflammatory cell phenotypes at baseline compared to screening
% of Screening Screening: concordance for 4 inflammatory cell phenotypes
Baseline Eos < 3 %; PMN < 60 % Eos < 3 %; PMN≥ 60 % Eos > =3 %; PMN≥ 60 % Eos ≥ 3 %; PMN < 60 %
Eos < 3 %; PMN < 60 % 50 % 24 % 0 % 19 %
Eos < 3 %; PMN≥ 60 % 33 % 62 % 29 % 25 %
Eos≥ 3 %; PMN≥ 60 % 0 % 10 % 57 % 6 %
Eos≥ 3 %; PMN < 60 % 17 % 5 % 14 % 50 %
% of Screening Screening: concordance for 2 inflammatory phenotypes
Baseline Eos < 3 % Eos≥ 3 % PMN < 60 % PMN≥ 60 %
Eos < 3 % 84 % 39 %
Eos≥ 3 % 16 % 61 %
PMN < 60 % 68 % 25 %
PMN≥ 60 % 33 % 75 %
Table 5 Concordance for the 4 and 2 sputum inflammatory cell phenotypes at 6 months compared to screening
% of Month 6 Month 6 concordance for 4 sputum inflammatory cell phenotypes
Screening Eos < 3 %; PMN < 60 % Eos < 3 %; PMN≥ 60 % Eos ≥ 3 %; PMN > =60 % Eos ≥ 3 %; PMN < 60 %
Eos < 3 %.; PMN < 60 % 77 % 8 % 15 % 0 %
Eos < 3 %; PMN≥ 60 % 43 % 43 % 14 % 0 %
Eos≥ 3 %; PMN≥ 60 % 0 % 57 % 29 % 14 %
Eos≥ 3 %; PMN < 60 % 21 % 0 % 7 % 71 %
% of Month 6 Month 6 concordance for 2 sputum inflammatory cell phenotypes
Screening Eos < 3 % Eos≥ 3 % PMN < 60 % PMN≥ 60 %
Eos < 3 % 85 % 15 %
Eos≥ 3 % 33 % 67 %
PMN < 60 % 85 % 15 %
PMN≥ 60 % 29 % 71 %
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other features of asthma were present, historical revers-
ibility documented, or AHR demonstrated. Similarly, the
spontaneous variation in both FEV1 and BDR even in
severe asthma suggests that low FEV1 should not neces-
sarily be a prerequisite for inclusion of patients into se-
vere asthma studies.
In general, the ACQ only demonstrated moderate sta-
bility across severities which may be related to the inher-
ent variability in asthma driven by seasonal exposures,
climatic factors, and infections. The controlled pheno-
type (ACQ < 1.5) was more stable in mild and moderate
asthma than in severe asthma while these 2 cohorts
showed less stability for the uncontrolled phenotype
(ACQ ≥ 1.5). This suggests that lack of control in mild
and moderate asthma was not always a persistent state.
In severe asthma, those who were uncontrolled in gen-
eral remained so, perhaps reflecting the persistent sever-
ity of the disease despite high-dose inhaled
corticosteroid therapy, and in many cases a lack of ap-
propriate targeted therapy for this challenging group of
patients.
FENO and the FENO-high categorization both showed
reasonable stability in moderate and severe asthma sug-
gesting that the FENO-high phenotype is a useful
phenotype and could be used reliably to select patients
for therapeutics as has been reported with ICS therapy
[19] and other type-2 therapies [1]. In the mild asthma
cohort, whose subjects were not treated with ICS during
the study, FENO-high concordance was slightly lower
perhaps due to the lack of anti-inflammatory therapy.
Others have also found FENO to be reasonably stable
over time [20–22]. Of note, a high proportion of patients
had consistently low FENO, perhaps indicating that
non-eosinophilic asthma was common.
When evaluating four sputum inflammatory pheno-
types, the picture that emerges is one of inherent vari-
ability in agreement with the findings of Al-Samri et al
[23], thus casting doubt as to whether these phenotypes
will prove to be useful long-term patient-selection strat-
egies. Thus comparing baseline to screening, the neutro-
philic phenotype was the most stable however when
comparing 6-month to screening-BL, the eosinophilic
phenotype was the most stable. Reducing the number of
sputum phenotypes to two, namely EOS with or without
NEU, or NEU with or without EOS, the ranking of the
concordances showed no consistent pattern. Reasons for
this could include spontaneous variability, seasonal
change, climate change, patient adherence, intercurrent
infections, as well as technical issues affecting sample
quality.
Others have reported on the stability or lack thereof of
clinical and biomarker characteristics in asthma. Blood
eosinophils were only measured during screening in
ADEPT but published data suggest substantial variability
even during a 24 h period [24] again raising the question
as to whether eosinophilic asthma, defined by bEOS, is a
stable phenotype. Fleming et al reported low reproduci-
bility for sputum eosinophils in children [25] as did Ros-
sall et al in adults with moderate to severe asthma [26].
In contrast Simpson et al found these measures to be
stable in adults with stable asthma [27].
The variability seen in ADEPT and in other studies for
the profile of inflammatory cells in sputum probably re-
flects similar factors that contribute to variability in
asthma e.g. allergen exposure, viral infections and tech-
nical issues with sputum induction. Thus, seasonal aller-
gen exposure could enhance Type 2 inflammation
resulting in greater eosinophilic inflammation and eleva-
tions in FENO as previously described. Viral infections,
which also have a seasonal pattern, could drive neutro-
philic inflammation that could persist after clinical
resolution.
Due to protocol restrictions for safety reasons in those
undergoing bronchoscopy, the ADEPT asthma cohort
did not include subjects with a BMI > 32 kg/m2, those
>65 years of age, current smokers and those on oral cor-
ticosteroids. The findings may therefore not be applic-
able in their entirety to severe refractory asthma.
Conclusions
In summary, the ADEPT asthma cohort presented a
unique opportunity to follow clinical status and bio-
markers in a well-characterized cohort over 12 months.
ADEPT confirms substantial variability in clinical char-
acteristics but importantly in clinical biomarkers as well
suggesting, that biological phenotypes are highly variable
in some patients, perhaps related to the same seasonal
changes that drive clinical variability. The implications
for using biomarkers assessed at a single time point may
be profound.
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